Topoisomerase IIα expression correlates with diminished disease-free survival in invasive breast cancer

International Journal of Radiation Oncology Biology Physics

Volumn 65, Issue 5, 2006, Pages 1411-1415

  O'Connor, John K ^a   Hazard, Lisa J ^b   Avent, James M ^c   Lee, R Jeffrey ^c   Fischbach, Jennifer ^c   Gaffney, David K ^b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c LDS HOSPITAL   (United States)

Author keywords

Breast cancer; Survival; Topoisomerase II

Indexed keywords

DISEASE CONTROL; DNA; ENZYMES; PATHOLOGY; PATIENT TREATMENT; RADIOTHERAPY; TUMORS;

BREAST CANCER; DISEASE FREE SURVIVAL; MOLECULAR TARGET; PATHOLOGIC FACTORS;

ONCOLOGY;

DNA TOPOISOMERASE (ATP HYDROLYSING); PARAFFIN; TOPOISOMERASE 2ALPHA; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; ANALYTIC METHOD; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER SURVIVAL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MASTECTOMY; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR CELL; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; ENZYMOLOGY; METABOLISM; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY;

ADULT; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; MASTECTOMY; RADIOTHERAPY, ADJUVANT; TUMOR MARKERS, BIOLOGICAL;

EID: 33748575904     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.02.045     Document Type: Article

References (21)

1. American Cancer Society. http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_breast_cancer_5.asp. Accessed February 9, 2006.
2. Simpson J.F., Gray R., Dressler L.G., et al. Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer. Results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol 18 (2000) 2059-2069
3. Berger J.M., Gamblin S.J., Harrison S.C., et al. Structure and mechanism of DNA topoisomerase II. Nature 379 (1996) 225-232 [Published erratum appears in Nature 1996;380:179]
4. Kellner U., Sehested M., Jensen P.B., et al. Culprit and victim-DNA topoisomerase II. Lancet Oncol 3 (2002) 235-243
5. Lynch B.J., Guinee D.G., and Holden J.A. Human DNA topoisomerase II-alpha. A new marker of cell proliferation in invasive breast cancer. Hum Pathol 28 (1997) 1180-1188
6. Jarvinen T.A., Kononen J., Pelto-Huikko M., et al. Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol 148 (1996) 2073-2082
7. Durbecq V., Desmed C., Paesmans M., et al. Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer. Int J Oncol 25 (2004) 1473-1479
8. MacGrogan G., Rudolph P., de Mascarel I., et al. DNA topo-isomerase IIalpha expression and the response toprimary chemotherapy in breast cancer. Br J Cancer 89 (2003) 666-671
9. Gaffney D.K., Leavitt D.D., Tsodikov A., et al. Electron arc irradiation of the postmastectomy chest wall with CT treatment planning. 20-Year experience. Int J Radiat Oncol Biol Phys 51 (2001) 994-1001
10. Thor A.D., Berry D.A., Budman D.R., et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90 (1998) 1346-1360
11. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study [Abstract]. Presented at San Antonio Breast Cancer Symposium. San Antonio, TX. Thursday, December 8, 2005.
12. Benjamin C.W., Hiebsch R.R., and Jones D.A. Caspase activation in MCF7 cells responding to etoposide treatment. Mol Pharmacol 53 (1998) 446-450
13. Holden J.A. DNA topoisomerases as anticancer drug targets. From the laboratory to the clinic. Curr Med Chem Anti-Canc Agents 1 (2001) 1-25
14. Davies S.M., Robson C.N., Davies S.L., et al. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem 263 (1988) 17724-17729
15. Potmesil M., Hsiang Y.H., Liu L.F., et al. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 48 (1988) 3537-3543 [Published erratum appears in Cancer Res 1988;48:4716]
16. Nitiss J.L., Liu Y.X., Harbury P., et al. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res 52 (1992) 4467-4472
17. Zhou Z., Zwelling L.A., Kawakami Y., et al. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells. Cancer Res 59 (1999) 4618-4624
18. Stacey D.W., Hitomi M., and Chen G. Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity. Mol Cell Biol 20 (2000) 9127-9137
19. Martin-Richard M., Munoz M., Albanell J., et al. Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. Oncology 66 (2004) 388-394
20. Depowski P.L., Rosenthal S.I., Brien T.P., et al. Topoisomerase IIalpha expression in breast cancer. Correlation with outcome variables. Mod Pathol 13 (2000) 542-547
21. Koren R., Rath-Wolfson L., Ram E., et al. Prognostic value of Topoisomerase II in female breast cancer. Oncol Rep 12 (2004) 915-919